

CURRICULUM VITAE
Jeffrey James Swigris, DO, MS

I. Personal History

Present Position Rank: Professor of Medicine
Present Affiliation: National Jewish Health
1400 Jackson Street, Southside #G07
Denver, Colorado 80206
Citizenship: USA

II. Educational History

1992 B.S. (Mathematics), B.A. (Biology)
Quincy College (now University); Quincy, Illinois
1996 D.O.
Ohio University College of Osteopathic Medicine; Athens, Ohio
07/1996 – 06/1997 Osteopathic internship, Internal Medicine Track Internship Program,
Ohio University—in affiliation with Grandview Hospital and Medical
Center; Dayton, Ohio
07/1997 – 06/2000 Resident, Internal Medicine Residency Program
Cleveland Clinic Foundation; Cleveland, Ohio
07/2000 – 06/2003 Postdoctoral fellow, Pulmonary and Critical Care Medicine
Stanford University; Stanford, California
07/2003 – 06/2004 Postdoctoral research fellow, Pulmonary and Critical Care Medicine
Stanford University; Stanford, California
2004 M.S. (Epidemiology)
Department of Health Research and Policy
Stanford University; Stanford, California

Licensure and Certification

1996 Medical Licensure, Ohio (training certificate—inactive)
2000 Medical Licensure, California (inactive)
2000 Diplomate, American Board of Internal Medicine (ABIM) (inactive)
2012 Diplomate, ABIM, Subspecialty of Pulmonary Diseases
2003 Diplomate, ABIM, Subspecialty of Critical Care Medicine (inactive)
2005 Medical Licensure, Colorado

III. Professional Positions

07/2003 – 07/2005 Clinical Instructor, Division of Pulmonary and Critical Care Medicine
Stanford University
08/2005 – 02/2011 Assistant Professor, Interstitial Lung Disease Program,
Division of Pulmonary Medicine, Department of Medicine,

	National Jewish Health
02/2006 – 07/2011	Assistant Professor, Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Health Sciences Center
06/2006 – 06/2007	Associate Program Director, Pulmonary and Critical Care Medicine Fellowship University of Colorado
11/2007 – 2014	Director, Interstitial Lung Disease Visiting Fellow’s Program, Division of Pulmonary Medicine, Department of Medicine National Jewish Health
07/2011 – 06/2019	Associate Professor, Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Health Sciences Center
02/2011 – 06/2019	Associate Professor, Interstitial Lung Disease Program, Division of Pulmonary Medicine, Department of Medicine, National Jewish Health
01/2015 – 06/2021	Director, Interstitial Lung Disease Program, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health
06/2019 – 11/2021	Professor, Interstitial Lung Disease Program, Division of Pulmonary Medicine, Department of Medicine, National Jewish Health
11/2021– present	Professor (by affiliation), Interstitial Lung Disease Program, Division of Pulmonary Medicine, Department of Medicine, National Jewish Health
12/2021 – present	Director, Therapeutic Area, Respiratory IPF/ILD Clinical Development and Medical Affairs Boehringer-Ingelheim Pharmaceuticals, Inc.

IV. Honors and Awards

1990	Nomination, NCAA Division II Academic All-American (Baseball)
1992	<i>Magna Cum Laude</i> graduate, Quincy College
1996	Phi Kappa Phi, Ohio University Chapter National Honor Society
1996	Top 10% Ohio University College of Osteopathic Medicine, Class of 1996
1997	Internal Medicine Fast Track Intern of the Year, Grandview Hospital
2000	Senior Medical Resident of the Year, Cleveland Clinic Foundation
2002	Nomination, Housestaff and Medical Student Clinical Teaching Award Stanford School of Medicine

2002	Dean's Fellowship Award for Clinical Research Stanford School of Medicine (declined)
2003	Nomination, Housestaff and Medical Student Clinical Teaching Award Stanford School of Medicine
2005	Faculty Teaching Award, Division of Pulmonary and Critical Care Medicine Stanford School of Medicine
2006	Top Ten Poster, American College of Chest Physicians Annual Meeting; Salt Lake City, Utah
2008	Nomination, Internal Medicine Clinician of the Year National Jewish Health
2012	Nomination, Clinical Investigator of the Year National Jewish Health
2013-2014	Outstanding Contributions by a Subspecialist to Adult Ambulatory Care Clerkship Department of Medicine, University of Colorado School of Medicine
2019	National Jewish Health Service Excellence Hero (https://www.nationaljewish.org/service-excellence/overview)

V. Professional Affiliations

American College of Chest Physicians
American Thoracic Society
International Society for Quality of Life Research

VI. Professional Service and Committees

2006 – 2011	Medical Records Committee, National Jewish Health
2006 – 2012	ATS/ERS/JRS Multi-national Idiopathic Pulmonary Fibrosis Consensus Statement Writing Committee
2006 – 2012	Leader, Quality of Life Section; ATS/ERS/JRS Multi-national Idiopathic Pulmonary Fibrosis Consensus Statement Writing Committee
2009 – present	Member, American Thoracic Society, Behavioral Sciences Assembly
2010 – 2014	Member, American College of Chest Physicians, Interstitial and Diffuse Lung Disease NetWork Steering Committee
2010 – 2019	Member, Medical Advisory Board Pulmonary Fibrosis Foundation
2011 – 2018	Planning Committee, Clinical Problems Assembly, American Thoracic Society

2012 – 2015	Assembly Liaison, Clinical Problems Assembly, American Thoracic Society
2012 – 2016	Program Committee, Clinical Problems Assembly, American Thoracic Society
2011 – 2012	Document Development Group, Idiopathic Interstitial Pneumonia Classification Committee, American Thoracic Society
2012 – 2014	Multi-National Trial Steering Committee, Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
2015	Clinical Science Chair, LAMposium 2015; Chicago, Illinois
2014 – 2016	Steering Committee, PILOT (Pulmonary Fibrosis Identification: Lessons for Optimizing Treatment), France Foundation
2020	Development Team, LINK Service (Listen, Inform, Navigate, Knowledge) designed to facilitate communication between ICU service and families of patients suffering from COVID-19
2020	Volunteer, LIFT Project - to support trainee (Anesthesiology Fellow) during COVID19 pandemic

VII. Patents: None

VIII. Review and Referee Activities

Editorial appointments:

09/2007 – 02/2010	Associate Editor: Respiriology (Official Journal of the Asian Pacific Society of Respiriology)
2020 – 2021	Editorial Board CHEST, Diffuse Lung Disease Section

Grant reviewer:

2008 – 2016	Ad Hoc reviewer, National Institute for Health Research, Programme Grants for Applied Research; U.K.
2022	Ad Hoc reviewer, European Science Foundation, Junior Research Project Fundamental Research

PhD Thesis reviewer:

2016	Lauren Troy, "Supplemental Oxygen Therapy in Patients with Early Interstitial Disease: Physiological Effects during Exercise and Sleep" University of Sydney
------	--

Peer-reviewer (selected journals): American Journal of Respiratory and Critical Care Medicine, Annals of the American Thoracic Society, Arthritis Care and Research, Arthritis Research and Therapy, Chest, European Respiratory Journal, Health and Quality of Life Outcomes, Journal of Clinical Pathology, Respiratory Care, Respiratory Medicine, Respirology, Sarcoidosis Vasculitis and Diffuse Lung Diseases, Thorax, Treatments in Respiratory Medicine

IX. Teaching Activities

2003 – 2005	Attending physician, Chest Clinic Attending physician, Interstitial Lung Disease Clinic Stanford University Medical Center
Fall 2004	INDE 221: Human Health and Disease Instructor, Interdisciplinary Clinical and Pathological Lung Lab Stanford School of Medicine
Spring 2005	INDE 221: Human Health and Disease Instructor, Interdisciplinary Clinical and Pathological Lung Lab Stanford School of Medicine
2004 – 2005	Attending physician, Lung and Heart-lung Transplant Clinic Attending physician, Lung and Heart-lung Transplant Inpatient Service Attending physician, Pulmonary Consultation Service Attending physician, Pulmonary Hypertension Service All at Stanford University Medical Center
2005 – 2008	Moderator, UCHSC Pulmonary and CCM Fellow's Journal Club National Jewish Health and University of Colorado Health Sciences Center
April 2006	University of Colorado First Year Medical Students Pulmonary Physiology Case Discussions University of Colorado Health Sciences Center
07/2005 – present	Attending physician, Interstitial Lung Disease Clinic National Jewish Health; Denver, Colorado
12/2010	Integrated Clinicians Course (ICC 7002) Spirituality Panel, University of Colorado Denver
2007 – 2014	Director, Interstitial Lung Disease Visiting Fellow's Program, Division of Pulmonary Medicine, Department of Medicine, National Jewish Health
2007 – 2016	Adult Ambulatory Care Clerkship UCHSC Medical School Third-year Students

Advisees/Mentees:

1. Amy L. Olson, MD. 2006 – 2008. **Role:** Masters Thesis and Fellowship Advisory Committees.
Thesis title: Multiple cause mortality in idiopathic pulmonary fibrosis from 1992-2003.

2. Jeffrey Swick, BS. 2008. **Role:** Supervisor for summer research internship. Project title: Heart Rate Recovery after Six-Minute Walk Test Predicts Survival in Patients with Idiopathic Pulmonary Fibrosis.
3. David Sprunger, BS. 2009. **Role:** Supervisor for research project. Project title: Cognitive function is impaired in patients with idiopathic pulmonary fibrosis.
4. David Sprunger, BS. 2012. **Role:** Supervisor for medical student research project. Project title: The influence of etiology on prognosis in patients with UIP-pattern lung injury.
5. Tara Farnsworth, BS. 2014. **Role:** Supervisor for MPH Capstone project. Project title: Dyspnea in fibrosing interstitial lung disease.
6. Kaitlin Fier, BS. 2014. **Role:** Supervisor for MPH Capstone project. Project title: Hand-held spirometry in IPF.
7. Josh Solomon, MD. 2015 – 2019. **Role:** Primary Mentor K23 application. Project title: Discerning the link between autoimmunity and lung disease in rheumatoid arthritis
8. David Sprunger, MD. 2015 – 2017. **Role:** Supervisor for resident research project. Project title: Epidemiology of IPF: Fidelity of diagnostic coding.
9. Yosafe Wakwaya, MD. 2017 – 2020. **Role:** Fellowship research mentor. Project title: Gastroesophageal reflux in fibrosing ILD.
10. Bridget Graney, MD. 2016 – 2020. **Role:** Fellowship and junior faculty research mentor. Project title: Effects of informal caregiver characteristics on fibrosing ILD patient outcomes.
11. Esther DeBoer, MD. 2020 – 2021. **Role:** Fellowship research mentor team member.

Visiting Professorships:

1. 03/07/2008. New York Methodist Hospital. **Hosts:** Arthur Sung, MD and Suhail Raof, MD

Invited Lectures, Presentations at Meetings, Online Activities (extramural, selected):

1. "Quality of life in the IPF patient: the need for a new assessment tool." American Thoracic Society International Conference Scientific Symposium; Orlando, Florida; 05/2004
2. "Provisional domains for an idiopathic pulmonary fibrosis specific health-related quality of life instrument: the IPF self-administered questionnaire (IPF-SAQ)." American College of Chest Physicians Conference Abstract Slide Presentation; Seattle, Washington; 10/2004
3. "Health-related quality of life in patients with idiopathic pulmonary fibrosis." Pulmonary Research in Progress Seminar; National Jewish Medical and Research Center; Denver, Colorado; 04/2005
4. "Health-related quality of life in patients with idiopathic pulmonary fibrosis." American Thoracic Society International Conference Sunrise Seminar; San Diego, California; 05/ 2005
5. "Quality of life in patients with idiopathic pulmonary fibrosis." American Thoracic Society International Conference; Clinical Topics in Pulmonary Medicine; San Diego, California; 05/2006
6. "Interstitial lung disease." Colorado Society of Osteopathic Medicine Annual Meeting; Denver, Colorado; 09/2006

7. Interstitial lung disease update.” Pulmonary Update Conference for Primary Care Providers, Providence Everett Medical Group; Seattle, Washington; 11/2006
8. “Therapeutic options for scleroderma-related interstitial lung disease.” American Thoracic Society International Conference Sunrise Seminar; San Francisco, California; 05/2007
9. “Detective Work: Interstitial lung disease.” Ohio University College of Osteopathic Medicine Annual CME Meeting and All-class Reunion; Columbus, Ohio; 10/2007
10. “Interstitial lung disease for the Primary Care Provider.” Colorado Society of Osteopathic Medicine CME in the City, “An Annual Update in Primary Care;” Denver, Colorado; 10/2007
11. “LAM: A General Overview.” Denver Regional Tuberos Sclerosis Conference, presented by the Tuberos Sclerosis Alliance; Denver, Colorado; 04/2009
12. “Connective tissue disease-related interstitial lung disease.” American Thoracic Society International Conference Postgraduate Course; San Diego, California; 05/2009
13. “Pulmonary rehabilitation for idiopathic pulmonary fibrosis.” American Thoracic Society International Conference Sunrise Seminar; San Diego, California; 05/2009
14. “Pulmonary fibrosis.” American College of Osteopathic Internists Conference and Convention; Tucson, Arizona; 10/2009
15. “The nuts and bolts of idiopathic pulmonary fibrosis.” Exempla Good Samaritan Medical Center Grand Rounds; Lafayette, Colorado; 09/2010
16. “Planning for a Happy Life: Rehabilitation, Sleep, and Other Factors Impacting Quality of Life.” American College of Chest Physicians Conference; Vancouver, BC; 11/2010
17. “Pulmonary rehabilitation and supportive care in the management of IPF.” American College of Chest Physicians Conference; Vancouver, BC; 11/2010
18. “Lymphoid interstitial pneumonia.” American Thoracic Society International Conference Scientific Symposium; Denver, Colorado; 05/2011
19. “Pulmonary rehabilitation and supportive care in the management of interstitial lung disease.” American College of Chest Physicians Conference Postgraduate Course; Honolulu, HI; 10/2011
20. “Nonspecific interstitial pneumonia.” Session Chair, American College of Chest Physicians Conference Symposium; Honolulu, HI; 10/2011
21. “The Whys and Hows of HRQL Assessment in Sarcoidosis.” Meeting of the World Association of Sarcoidosis and Other Granulomatous Disorders; Cleveland, OH; 10/2012
22. “The race/ethnicity gap in outcomes in pulmonary fibrosis.” American College of Chest Physicians Conference Symposium; Atlanta, GA; 10/2012
23. “Health-related quality of life in LAM: what is it? how do we measure it? does it matter?” LAMposium 2013; Cincinnati, Ohio; 04/2013
24. “Pathogenesis of usual interstitial pneumonia: idiopathic vs. CTD.” Sixth Course of Respiratory Diseases Center and First of the Rheumatologic Unit of Clinica Las Condes; Santiago, Chile; 08/2013
25. “Pulmonary involvement in Poly-/Dermatomyositis and anti-synthetase syndrome. Sixth Course of Respiratory Diseases Center and First of the Rheumatologic Unit of Clinica Las Condes; Santiago, Chile; 08/2013
26. “Controversies in IPF and CTD-UIP.” Sixth Course of Respiratory Diseases Center and First of the Rheumatologic Unit of Clinica Las Condes; Santiago, Chile; 08/2013
27. “Bronchiolitis in connective tissue disease.” Sixth Course of Respiratory Diseases Center and First of the Rheumatologic Unit of Clinica Las Condes; Santiago, Chile; 08/2013

28. "Treatment of connective tissue disease-related interstitial lung disease." Sixth Course of Respiratory Diseases Center and First of the Rheumatologic Unit of Clinica Las Condes; Santiago, Chile; 08/2013
29. "Overview of Idiopathic Pulmonary Fibrosis (IPF)." ProEd CME Program; Oklahoma City, Oklahoma 03/2014
30. "Pharmacological Management of IPF." ProEd CME Program; Oklahoma City, Oklahoma 03/2014
31. "The in's and out's of oxygen in IPF." Webinar sponsored by the Pulmonary Fibrosis Foundation; 08/2014
32. "PILOT Regional Summit, Denver CO." Co-Chair; Denver, Colorado; 03/2015
33. "EXPLORE IPF Learning Theater: Understanding the Patient & Caregiver Perspective." American College of Chest Physicians Conference; Austin, Texas; 10/2014
34. "A NEW ERA in IPF." Four webinars sponsored by the France Foundation; 12/10/2014, 12/16/2014, 12/17/2014, 12/22/2014
35. "IPF 101: The Basics of Idiopathic Pulmonary Fibrosis." Genentech Masters Faculty Day Presentation; Genentech, Inc.; South San Francisco, California 12/2014
36. "Update on idiopathic pulmonary fibrosis." Keystone Conference; Keystone, Colorado; 02/2015
37. "Connective tissue disease-related interstitial lung disease: case discussions." Keystone Conference; Keystone, Colorado; 02/2015
38. "Incorporating patient-reported outcomes in LAM (lymphagioleiomyomatosis) research." LAMposium 2015; Chicago, Illinois; 03/2015
39. "Health-related quality of life in LAM (lymphagioleiomyomatosis)." LAMposium 2015; Chicago, Illinois; 03/2015
40. "Mastering Clinical Challenges in the Management of Idiopathic Pulmonary Fibrosis: A Multidisciplinary Approach." CME Webinar sponsored by MED-IQ; 03/2015
41. "Quality of Life for Patients with IPF: Therapeutic Needs vs. Palliative Care". Postgraduate Course, International Conference of the American Thoracic Society ; Denver, Colorado; 05/2015
42. IPF Expert Perspective: Clinical Features, Progression, and Monitoring of Disease; ATS 2015; Denver, Colorado; 05/2015
43. "Update on idiopathic pulmonary fibrosis." Dignity Health, St. Joseph's Hospital Advanced Lung Disease and Lung Transplant Symposium; Phoenix, Arizona 02/2016
44. "Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy." The 40th Annual National Jewish Health Pulmonary and Allergy Update; Keystone, Colorado 02/2017
45. "Idiopathic Pulmonary Fibrosis." Annual National Jewish Health Pulmonary and Allergy Update; Keystone, Colorado 02/2018
46. "Diffuse Cystic Lung Disease." Core Curriculum Track, International Conference of the American Thoracic Society; San Diego, California; 05/2018
47. Podcasts: with Aryeh Fischer. Three separate podcasts on Scleroderma ILD; 11/2018
48. "The Effect of Oxygen on Quality of Life Among Oxygen Users and their Caregivers"; Scientific Symposium, International Conference of the American Thoracic Society; Dallas, Texas; 05/2019

49. Podcast: with Amy Olson and Katie Rosen. "Interstitial Pneumonia with Autoimmune Features (IPAF): A Research Classification" <https://reachmd.com/programs/cme/interstitial-pneumonia-with-autoimmune-features-ipaf-a-research-classification/10943/>
50. Chair, CME program: Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): A Multidisciplinary Approach to Diagnosis and Longitudinal Management; New Orleans, Louisiana; 10/2019
51. Podcast: with Elizabeth Redente. Dialogue with a Doc: COVID-19 and Beyond. Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). February 18, 2021

Lectures, Presentations and Online Courses (intramural, selected):

1. "Lymphoid interstitial pneumonia." Pulmonary and Critical Care Medicine Grand Rounds Stanford School of Medicine, Stanford, California; 01/2001
2. "Health-related quality of life in patients with idiopathic pulmonary fibrosis." Rheumatology Grand Rounds; UCHSC; Denver, Colorado; 04/2006
3. "Idiopathic pulmonary fibrosis" Pulmonary and Critical Care Medicine Grand Rounds; Stanford School of Medicine, Stanford, California; 04/2001
4. "IPF: clinical year in review." Pulmonary and Critical Care Medicine Grand Rounds; Stanford School of Medicine, Stanford, California; 04/2002
5. "Barriers to clinical research in idiopathic pulmonary fibrosis." Research in Progress Seminar; Department of Epidemiology, Stanford School of Medicine, Stanford, California; 02/2003
6. "Patient-assessed outcomes in patients with idiopathic pulmonary fibrosis." Pulmonary and Critical Care Medicine Research in Progress Seminar; Stanford School of Medicine, Stanford, California; 05/2003
7. "What's new in IPF? Update from the 2004 ATS Conference." Stanford IPF Support Group Meeting; Stanford, California; 06/2004
8. "Medications for IPF." Stanford IPF Support Group Meeting; Stanford, California; 04/2005
9. "Health-related quality of life in patients with idiopathic pulmonary fibrosis." Pulmonary and Critical Care Grand Rounds; VA Palo Alto Health Care System; Palo Alto, California; 06/2005
10. "Fibrosis and the idiopathic interstitial pneumonias." Topics in Pulmonary Medicine Lecture Series; UCHSC; Denver, Colorado; 04/2007
11. "Management of Connective Tissue Disease-Related Interstitial Lung Disease." Rheumatologic Lung Symposium: Interstitial Lung Disease and Pulmonary Hypertension; National Jewish Health; Denver, Colorado; 09/2008
12. "Health-related Quality of Life in IPF." National Jewish Health Medicine Grand Rounds; National Jewish Health; Denver, Colorado; 03/18/2013
13. "Pharmacological treatment of IPF." Best Practices in Caring for Patients with Idiopathic Pulmonary Fibrosis; Fort Collins, Colorado; 03/20/2013
14. "Non-pharmacological treatment of IPF." Best Practices in Caring for Patients with Idiopathic Pulmonary Fibrosis; Fort Collins, Colorado; 03/20/2013
15. "Optimizing Management of Idiopathic Pulmonary Fibrosis (IPF) Through Effective Healthcare Provider–Patient Communication"; Active online November 2017
16. "Diagnosing IPF." Best Practices in Caring for Patients with Idiopathic Pulmonary Fibrosis; National Jewish Health; Denver, Colorado; 11/15/2017

17. "Creating Patient-Centered Educational Resources: Insights from an Interdisciplinary Quality Improvement Initiative at NJH" Grand Rounds; National Jewish Health; Denver, Colorado; 03/19/2018

X. Research Grants, Contracts, and Special Grants

1. Automated Long-Term Oxygen Therapy Control System

Role: Co-Investigator

Agency: 1R43HL160356-01

Term: 09/01/2021 – 07/31/2022

Total Award: \$299,311

Project Summary: In this project, we aim to develop a closed-loop supplemental oxygen delivery device that automatically adjusts oxygen flow rate to meet patients' needs.

2. *The Role of Laryngopharyngeal Reflux in Idiopathic Pulmonary Fibrosis*

Role: Principal Investigator

Agency: Boehringer Ingelheim

Term: 12/2017 – 11/2021

Total Award: \$500,000

Project Summary: In this project, we aim to determine the association between LPR and IPF disease severity and risk of progression.

3. NIH 1UG3TR002445-01 *Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis*

Role: Co-I (Downey, Dudley, Kaminski)

Agency: NIH

Term: 04/10/2018 to 03/31/2019

Total Award: \$853,963.00

Project Summary: In this project, we aim to assess anti-fibrotic properties of saracatinib in cell and murine models of pulmonary fibrosis.

4. *Right Flow Oxygen Delivery Device*

Role: Co-I (Brown)

Agency: State of Colorado Office of Economic Development and International Trade Grant

Agreement with National Jewish Health

Term: 07/01/2015 to 04/30/2018

Total Award: \$18,375.00

Project Summary: In this project, we aim to develop a device that self-adjusts oxygen flow to meet the demands of patients with pulmonary fibrosis who use supplemental oxygen.

5. *Optimizing Management of Idiopathic Pulmonary Fibrosis through Effective Healthcare Provider-Patient Communication*

Role: Principal Investigator

Agency: Genentech

Term: 04/15/2016 – 04/15/2017

Total Award: \$299,000.00

Project Summary: In this project, we aim to improve understanding of educational- and disease management resource-needs, and to devise strategies to meet those needs, of patients with idiopathic pulmonary fibrosis.

6. PCORI CE-12-11-4134 (*P4f*) *Patient Participation Program for Pulmonary Fibrosis: Assessing the Effects of Supplemental Oxygen*

Role: Principal Investigator

Agency: PCORI (Patient Centered Outcomes Research Institute)

Term: 08/01/2013 – 07/30/2016

Total Award: \$1,277,948.00

Project Summary: In this project, we aim to determine the effect of supplemental oxygen on a range of outcomes in patients with pulmonary fibrosis.

7. NIH K23HL092227 *Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis*

Role: Principal Investigator

Agency: NIH

Term: 07/15/2009 to 06/30/2014

Total Award: \$658,947

Project Summary: In this project, we assessed the beneficial effects of a standardized pulmonary rehabilitation program on a range of outcomes in patients with various forms of interstitial lung disease.

8. *Development of a LAM-specific instrument to assess health-related quality of life*

Role: Principal Investigator

Agency: LAM Foundation

Term: 03/01/2013 – 08/28/2014

Total Award: \$31,956

Project Summary: In this project, we conducted focus groups with LAM patients and developed a LAM-specific health-related quality of life questionnaire (ATAQ-LAM).

9. *Using Patient and Caregiver Perceptions to Revise the ATAQ-IPF*

Role: Principal Investigator

Agency: Intermune

Term: 08/01/2012 to 07/31/2013

Total Award: \$88,000

Project Summary: In this project, we conducted focus groups with IPF patients and their informal caregivers to gain an improved understanding of what living with IPF holds for patients and their family members; we used that information to revise a disease-specific health-related quality of life instrument (ATAQ-IPF).

10. NIH R21AR057448 *Cardiopulmonary Correlates of Cognitive Function in SLE*

Role: Co-I (Kozora)

Agency NIH

Term: 9/27/2010 to 5/31/2012

Annual Award: \$166,148

Project Summary: In this project, we assessed cognitive function in patients with SLE and determined the effects of exercise on cognitive function.

11. *Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis*

Role: Principal Investigator

Agency: Mordecai Palliative Care Research Fund (UCHSC)

Term: 02/01/2008 to 02/01/2009

Total Award: \$50,000

Project Summary: In this project, we assessed the beneficial effects of a standardized pulmonary rehabilitation program on a range of outcomes in patients with various forms of interstitial lung disease.

XI. Bibliography

Research papers published in refereed journals

1. **Swigris JJ**, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. *Thorax* 2005;60:588-594 PMID: 20921071
2. **Swigris JJ**, Stewart AL, Gould MK, Wilson SR. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. *Health Qual Life Outcomes* 2005;3:61 PMID: 16212668 PMCID: PMC1276807
3. **Swigris JJ**, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK. Mycophenolate mofetil is safe, well-tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. *Chest* 2006;130:30-36 PMID: 1840379
4. Fischer A, Misumi, S, Curran-Everett D, Meehan RT, Ulrich SK, **Swigris JJ**, Frankel SK, Cosgrove GP, Lynch DA, Brown KK. Pericardial abnormalities predict the presence of echocardiographically-defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease. *Chest* 2007;131:988-992. PMID: 17426200
5. Olson AL, **Swigris JJ**, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality Rates from Pulmonary Fibrosis Increased from 1992 to 2003 in the U.S. *Am J Respir Crit Care Med* 2007; 176:277-284. PMID: 18689582
6. Fischer A, **Swigris JJ**, Groshong SD, Cool CD, Sahin H, Lynch DA, Curran-Everett D, Gillis JZ, Meehan RT, Brown KK. Clinically Significant Interstitial Lung Disease in Limited Scleroderma: Histopathology, Clinical Features, and Survival. *Chest* 2008;134:601-605. PMID: 18403656
7. Olson AL, **Swigris JJ**, Raghu G, Brown KK. Seasonal Variation: Mortality from Pulmonary Fibrosis is Greatest in the Winter. *Chest* 2009;136:16-22 PMID: 18689582 PMCID: PMC3662208
8. **Swigris JJ**, Zhou X, Wamboldt FS, du Bois R, Keith R, Fischer A, Cosgrove GP, Frankel SK, Curran-Everett D, Brown KK. Exercise SpO₂ Accurately Reflects SaO₂ and Predicts Mortality in Systemic Sclerosis. *Thorax* 2009;64:626-630 PMID: 19359369 PMCID: PMC3667987
9. **Swigris JJ**, Swick J, Wamboldt FS, Sprunger DS, du Bois R, Fischer A, Cosgrove GP, Frankel SK, Fernandez-Perez E, Kervitsky D, Brown KK. Heart Rate Recovery after Six-Minute Walk Test Predicts Survival in Patients with Idiopathic Pulmonary Fibrosis. *Chest* 2009;136:841-848 PMID: 19395579 PMCID: PMC2775995
10. Fischer A, **Swigris JJ**, du Bois R, Lynch D, Downey GP, Cosgrove GP, Frankel SK, Fernandez-Perez E, Gillis JZ, Brown KK. Anti-Synthetase Syndrome in ANA and anti-JO-1 Negative

- Patients Presenting with Idiopathic Interstitial Pneumonia. *Respir Med* 2009;103:1719-1724 PMID: 19497723 PMCID: PMC2857337
11. Fischer A, **Swigris JJ**, du Bois RM, Groshong SD, Cool CD, Sahin H, Lynch DA, Gillis JZ, Cohen MD, Meehan RT, Brown KK. Minor Salivary Gland Biopsy To Detect Primary Sjogren Syndrome in Patients With Interstitial Lung Disease. *Chest* 2009;136:1072-1078 PMID: 19429722 PMCID: PMC3662204
 12. **Swigris JJ**, Wamboldt FS, Behr J, du Bois R, King, Jr. TE, Raghu G, Brown KK. The six-minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. *Thorax* 2010;65:173-177 PMID: 19996335 PMCID: PMC3144486
 13. **Swigris JJ**, Brown KK, Behr J, du Bois R, King, Jr. TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. *Respir Med* 2010;104:296-304 PMID: 19815403 PMCID: PMC2856332
 14. Raghu G, King, Jr. TE, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, **Swigris JJ**. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). *Eur Respir J* 2010;35:118-123 PMID: 19679600 PMC: PMC2848824
 15. Han MK, **Swigris JJ**, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Flaherty KR, Martinez FJ. Gender influences health-related Quality of Life in IPF. *Respir Med* 2010;124:724-730 PMID: 20036113 PMCID: PMC 2862780
 16. **Swigris JJ**, Yorke J, Sprunger DB, Swearingen C, Pincus T, du Bois RM, Brown KK, Fischer A. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. *Respir Med* 2010;104:1350-1355 PMID: 20471238 PMCID: PMC2914213
 17. Yorke J, Jones PW, **Swigris JJ**. Development and Validity Testing of an IPF Specific Version of the SGRQ. *Thorax* 2010;65:921-926. PMID:20861296 PMCID: PMC3697105
 18. **Swigris JJ**, Wilson SR, Green KE, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life Outcomes* 2010;8:77 PMID: 20673370 PMCID: PMC2920246
 19. Yorke J, **Swigris JJ**, Russell AM, Moosavi S, Ng MK, Longshaw M, Jones PW. Dyspnoea-12 is a valid and reliable measure of breathlessness in patients with ILD. *Chest* 2011;139:159-164 PMID: 20595454 PMCID: PMC3035488
 20. Olson AL, **Swigris JJ**, Sprunger, DB, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK. Rheumatoid Arthritis-Interstitial Lung Disease-Associated Mortality. *Am J Respir Crit Care Med* 2011;183:372-278 PMID: 20851924
 21. **Swigris JJ**, Fairclough D, Morrison M, Make B, Kozora E, Brown KK, Wamboldt. Benefits of pulmonary rehabilitation in IPF. *Respir Care* 2011;56:783-789 PMID:21333082
 22. **Swigris JJ**, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart Rate Recovery after 6MWT Predicts Pulmonary Hypertension in Patients with IPD. *Respirology* 2011;16:439-445. PMID:20946337
 23. **Swigris JJ**, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger, DB, Brown KK. Sarcoidosis-related mortality in the U.S. from 1988-2007. *Am J Respir Crit Care Med* 2011;183:1524-1530 PMID:21330454 PMCID: PMC3137141
 24. **Swigris JJ**, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger, DB, Brown KK. Increased risk for pulmonary embolism among US decedents with sarcoidosis from 1988-2007. *Chest* 2011;140:1261-1266 PMID: 21565969 PMCID: PMC3205849

25. Ganesh Raghu, Harold R. Collard, Jim J. Egan, Fernando J. Martinez, Juergen Behr, Kevin K. Brown, Thomas V. Colby, Jean-François Cordier, Kevin R. Flaherty, Joseph A. Lasky, David A. Lynch, Jay H. Ryu, **Jeffrey J. Swigris**, Athol U. Wells, Julio Ancochea, Demosthenes Bouros, Carlos Carvalho, Ulrich Costabel, Masahito Ebina, David M. Hansell, Takeshi Johkoh, Dong Soon Kim, Talmadge E. King, Jr., Yasuhiro Kondoh, Jeffrey Myers, Nestor L. Müller, Andrew G. Nicholson, Luca Richeldi, Moisés Selman, Rosalind F. Dudden, Barbara S. Griss, Shandra L. Protzko, and Holger J. Schünemann on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. *Am J Respir Crit Care Med* 2011;183:788-824 PMID:21471066
26. Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon JJ, Brown KK, **Swigris JJ**. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. *Eur Respir J* 2012;39:125-132 PMID:21737559
27. Yorke J, Russell AM, **Swigris JJ** Moosavi S, Ng MK, Longshaw M, Jones PW. Assessment of dyspnea in asthma: validation of the Dyspnea-12. *J Asthma* 2011;48:602-608 PMID: 21737559 PMCID: PMC3149863
28. **Swigris JJ**, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger, DB, Brown KK. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. *Respir Med* 2012;106:588-593 PMID: 22296740 PMCID: PMC3294009
29. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Achcar RD, Brown KK, Martin RJ, **Swigris JJ**. Lung Disease with Anti-CCP Antibodies but not Rheumatoid Arthritis or Connective Tissue Disease. *Respir Med* 2012;106:1040-7 PMID: 22503074
30. Pillai M, Olson AL, Huie TJ, Solomon JJ, Fernandez-Perez ER, Brown KK, Hanna P, Lee-Chiong T, **Swigris JJ**. Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease. *Respir Med* 2012;106:1033-9 PMID: 22521226 PMCID: PMC3441137
31. **Swigris JJ**, Han ML, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough DL for the IPFnet. The UCSD Shortness of Breath Questionnaire has Longitudinal Construct Validity in Idiopathic Pulmonary Fibrosis. *Respir Med* 2012;106:1447-1455 PMID: 22801586 PMCID: PMC3441137
32. **Swigris JJ**, Lee HS, Cohen M, Inoue Y, Moss J, Singer L, Young LR, McCormack FX. St. George's Respiratory Questionnaire has Longitudinal Construct Validity in Lymphangioleiomyomatosis for the MILES trial investigators. *Chest* 2013;143:1671-8 PMID: 23328755 PMCID: PMC3673663
33. Fischer A, Solomon JJ, Olson AL, Fernandez-Perez ER, Huie TJ, Brown KK, Martin RJ, **Swigris JJ**. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. *J Rheumatol* 2013;40:640-6 PMID:23457378 PMCID: PMC3676865
34. Fernández Pérez ER, Krishnamoorthy M, Brown KK, Huie TJ, Fischer A, Solomon JJ, Meehan RT, Olson AL, Achcar RD, **Swigris JJ**. FEV1 over time in patients with connective tissue disease-related bronchiolitis. *Respir Med* 2013;107:883-9 PMID:23582575 PMCID: PMC3697096

35. Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, Curran-Everett D, Fischer A, **Swigris JJ**, Brown KK. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). *Respir Med* 2013 Jun 18. pii: S0954-6111(13)00174-1. doi: 10.1016/j.rmed.2013.05.002 PMID: 23791462
36. Fernández Pérez ER, **Swigris JJ**, Forssen AV, Tourin O, Solomon JJ, Huie TJ, Olson AL, Brown KK. Identifying an Inciting Antigen is Associated with Improved Survival in Patients with Chronic Hypersensitivity Pneumonitis. *Chest* 4 July 2013 12-2685 PMID: 23828161
37. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, **Swigris J**, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST. PMID:24032382 [PubMed - in process]
38. Young LR, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, **Swigris JJ**, Taveira-Dasilva AM, Krischer JP, Trapnell BC, McCormack FX. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *Lancet Respir Med*. 2013 Aug;1(6):445-452. PMID:24159565
39. Sprunger D, Fernandez-Perez E, **Swigris J**, Olson A. Idiopathic pulmonary fibrosis co-morbidity: thromboembolic disease and coronary artery disease. *Current Respiratory Care Reports*. 2013 Dec;2 (4):241-247. (submitted to PubMed)
40. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dearipa PF, Distlerl O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, **Swigris J**, Antoniou K, Baughman RP, Castellino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim Ds, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014 Jan 7. Doi: 10.1136/thoraxjnl-2013-204202. [Epub ahead of print] PMID: 24368713
41. Belkin A, Albright K, **Swigris JJ**. A qualitative study of informal caregivers' perspectives on the effects of idiopathic pulmonary fibrosis. *BMJ Open Resp Res* 2014; 1:e000007doi:10.1136/bmjresp-2013-000007
42. **Swigris JJ**, Steiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS; IPFnet investigators. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. *Respir Med* 2014 Jan;108(1):181-8. doi: 10.1016/j.rmed.2013.12.009. Epub 2013 Dec 24. PMID: 24388667
43. Belkin A, Albright K, Fier K, Desserich J, **Swigris JJ**. "Getting stuck with LAM": patients perspectives on living with Lymphangioleiomyomatosis. *Health Qual Life Outcomes* 2014 May 21;12:79. doi: 10.1186/1477-7525-12-79. PMID: 24885591

44. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, **Swigris JJ**, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. PMID: 24836312
45. Strand MJ, Sprunger D, Cosgrove GP, Fernandez-Perez ER, Frankel SK, Huie TJ, Olson AL, Solomon J, Brown KK, **Swigris JJ**. Pulmonary function and survival in idiopathic versus secondary usual interstitial pneumonia. *Chest* 2014 Apr 3. doi: 10.1378/chest.13-2388. PMID: 24700149
46. Fier K, Belkin A, Baird S, Crowe B, Eres L, Korn M, Maginn L, McCormick M, Vierzba T, Wamboldt FS, **Swigris JJ**. A pulmonary fibrosis contact registry. *J Clin Trials* 2014;4:4
47. Yorke J, Spencer LG, Duck A, Ratcliffe S, Kwong GN, Longshaw MS, Belkin A, **Swigris JJ**. Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA). *BMJ Open Resp Res* 2014;1:e000024 doi:10.1136/bmjresp-2014-000024
48. Fischer A, **Swigris JJ**, Bolster MB, Chung L, Csuka ME, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers LK, Gomberg-Maitland M, Mathai SC, Simms R, Steen VD. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. *Clin Exp Rheumatol* 2014 Nov-Dec;32(6 Suppl 86):S-109-14. Epub 2014 Nov 4. PMID: 25372796
49. Belkin A, Fier K, Albright K, Baird S, Crowe B, Eres L, Korn M, Maginn L, McCormick M, Root ED, Vierzba T, Wamboldt FS, **Swigris JJ**. Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis. *BMC Pulm Med* 2014 Nov 1;14:169. doi: 10.1186/1471-2466-14-169. PMID: 25361630
50. Carr LL, Chung JH, Duarte Achcar R, Lesic Z, Rho JY, Yagihashi K, Tate RM, **Swigris JJ**, Kern JA. The Clinical Course of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. *Chest* 2014 Oct 2. doi: 10.1378/chest.14-0711. [Epub ahead of print] PMID: 25275948
51. Kozora E, Zell J, **Swigris J**, Strand M, Duggan EC, Burleson A, Make B. Cardiopulmonary correlates of cognition in systemic lupus erythematosus. *Lupus* 2015 Feb;24(2):164-73. doi: 10.1177/0961203314551810. Epub 2014 Sep 23. PMID:25249596
52. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, **Swigris JJ**, Noble PW. Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. *Chest* 2015 Apr 9. doi: 10.1378/chest.14-2817. [Epub ahead of print] PMID:25856121
53. Olson AL, **Swigris JJ**, Belkin A, Hannen L, Yagihashi K, Schenkman M, Brown KK. Physical functional capacity in idiopathic pulmonary fibrosis: performance characteristics of the continuous-scale physical function performance test. *Expert Rev Respir Med* 2015 Apr 5:1-7. [Epub ahead of print] PMID:25843290
54. Strookappe B, Elfferich M, **Swigris J**, Verschoof A, Verschakelen J, Knevel T, Drent M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. *Sarc Vasc Diff Lung Dis* 2015;32:43-52
55. Strookappe B, **Swigris J**, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of Physical Training in Sarcoidosis. *Lung* 2015 Aug 19. [Epub ahead of print] PMID:26286208

56. Walker TD, Desserich J, Albright K, Wamboldt FS, Belkin A, Fier K, **Swigris JJ**. Development of ATAQ-LAM: a tool to assess quality of life in Lymphangiomyomatosis. *Health Qual Life Outcomes* 2015 Jul 30;13(1):112. doi:10.1186/s12955-015-0294-5. PMID: 26220448
57. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Streck ME, **Swigris JJ**, Wells AU, West SG, Collard HR, Cottin V; "ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD". An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J* 2015 Jul 9. pii: ERJ-00150-2015. doi: 10.1183/13993003.00150-2015. [Epub ahead of print] PMID: 26160873
58. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, **Swigris JJ**, Valeyre D, King TE Jr. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. *Eur Respir J* 2015 Dec 2. pii: ERJ-00026-2015. doi: 10.1183/13993003.00026-2015. [Epub ahead of print] PMID:26647432
59. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, **Swigris JJ**. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J* 2015 Nov 19. pii: ERJ-00357-2015. doi: 10.1183/13993003.00357-2015. [Epub ahead of print] PMID:26585429
60. Mittoo S, Frankel S, LeSage D, Strand V, Shah AA, Christopher-Stine L, Danoff S, Hummers LK, **Swigris JJ**, Huscher D, Christensen AM, Cenac SL, Erbil JK, Ferguson S, Garcia-Valladares I, Grewal HK, Orbai AM, Smith KC, Tran M, Bingham CO 3rd, Castelino FV, Fischer A, Saketkoo LA. Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). *Curr Respir Med Rev* 2015 Jun;11(2):175-183. PMID:26568747
61. Cao M, Wamboldt FS, Brown KK, Hickman J, Olson AL, Solomon JJ, **Swigris JJ**. Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users. *Multidiscip Respir Med* 2015 Nov 30;10:37. doi: 10.1186/s40248-015-0035-y. eCollection 2015. PMID:26693009
62. Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, **Swigris J**, Cella D. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. *Lung* 2016 Feb 9. [Epub ahead of print] PMID:26861885
63. Chartrand S, **Swigris JJ**, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. *Sarcoidosis Vasc Diffuse Lung Dis* 2016 Jan 15;32(4):296-304. PMID:26847096
64. Liu H, Patel D, Welch A, Wilson C, Mroz M, Li L, Rose C, VanDyke M, **Swigris J**, Hamzeh N, Maier LA. Association between Occupational Exposures and Sarcoidosis: an Analysis from Death Certificates in the United States, 1988-1999. *Chest* 2016 Jan 30. pii: S0012-3692(16)00514-6. doi: 10.1016/j.chest.2016.01.020. [Epub ahead of print] No abstract available. PMID:26836934
65. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, **Swigris JJ**, Valeyre D,

- Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. *BMJ Open Respir Res* 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016. PMID:26835133
66. Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, **Swigris JJ**. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. *BMC Pulm Med* 2016 Jan 5;16(1):2. doi: 10.1186/s12890-015-0165-1. PMID:26732054
67. Albright K, Walker T, Baird S, Eres L, Farnsworth T, Fier K, Kervitsky D, Korn M, Lederer DJ, McCormick M, Steiner JF, Vierzba T, Wamboldt FS, **Swigris JJ**. Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment. *BMC Pulm Med* 2016 Jan 12;16(1):4. doi: 10.1186/s12890-016-0167-7. PMID:26754048
68. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, **Swigris JJ**, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. *Thorax* 2016 Mar 11. pii: thoraxjnl-2015-207011. doi: 10.1136/thoraxjnl-2015-207011. [Epub ahead of print] PMID: 26968970
69. Chartrand S, **Swigris JJ**, Peykova L, Chung J, Fischer A. A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. *J Rheumatol* 2016 May;43(5):887-92. doi: 10.3899/jrheum.150966. PMID: 26932342
70. Mannina A, Chung JH, **Swigris JJ**, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson A, Cox CW, Kligerman SJ, Curran-Everett D, Fernández Pérez ER. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease. *Ann Am Thorac Soc* 2016 Apr 11. [Epub ahead of print] PMID:27064856
71. Morisset J, Dubé BP, Garvey C, Bourbeau J, Collard HR, **Swigris JJ**, Lee JS. The Unmet Educational Needs of Interstitial Lung Disease Patients: Setting the Stage for Tailored Pulmonary Rehabilitation. *Ann Am Thorac Soc* 2016 Apr 11. [Epub ahead of print] PMID:27064659
72. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, **Swigris JJ**. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. *Eur Respir J*. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28. PMID:27471208
73. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, **Swigris J**, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM; Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med*. 2016 Sep;4(9):708-19. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. PMID: 7469583
74. Cao M, **Swigris JJ**, Wang X, Cao M, Qiu Y, Huang M, Xiao Y, Cai H. Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. *Mediators Inflamm* 2016;2016:6940480. doi: 10.1155/2016/6940480. PMID: 27642238

75. Chartrand S, **Swigris JJ**, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. *Respir Med* 2016 Oct;119:150-154. doi: 10.1016/j.rmed.2016.09.002. PMID: 27692137
76. **Swigris JJ**, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. *Eur Respir J* 2017 Jan 18;49(1). pii: 1601788. doi: 10.1183/13993003.01788-2016. PMID:28100551
77. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, **Swigris JJ**, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. *Lancet Respir Med* 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. PMID:27876247
78. Natalini JG, **Swigris JJ**, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. *Respir Med* 2017;127:1-6. doi: 10.1016/j.rmed.2017.04.002. PMID:28502413
79. Ley B, **Swigris J**, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2017 May 4. doi: 10.1164/rccm.201701-0091OC. [Epub ahead of print] PMID:28471697
80. Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, **Swigris JJ**, Solomon JJ. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. *Respir Med* 2017;126:100-104. doi: 10.1016/j.rmed.2017.03.027. PMID:28427540
81. Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, **Swigris JJ**. Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis. *Heart Lung* 2017 Jul 31. pii: S0147-9563(17)30145-0. doi: 10.1016/j.hrtlng.2017.07.001. [Epub ahead of print] PMID:28774655
82. Kreuter M, **Swigris J**, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagemeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. *Respir Res* 2017 Jul 14;18(1):139. doi: 10.1186/s12931-017-0621-y. PMID:28709421
83. Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, **Swigris JJ**. Informal caregivers experience of supplemental oxygen in pulmonary fibrosis. *Health Qual Life Outcomes* 2017 Jul 1;15(1):133. doi: 10.1186/s12955-017-0710-0. PMID:28668090
84. Root ED, Graney B, Baird S, Churney T, Fier K, Korn M, McCormick M, Sprunger D, Vierzba T, Wamboldt FS, **Swigris JJ**. Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen. *BMC Pulm Med* 2017 Nov 23;17(1):154. doi: 10.1186/s12890-017-0495-2. PMID:29169394

85. Olson AL, Graney B, Baird S, Churney T, Fier K, Korn M, McCormick M, Sprunger D, Vierzba T, Wamboldt FS, **Swigris JJ**. Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis. *BMC Pulm Med* 2017 Nov 22;17(1):152. doi: 10.1186/s12890-017-0497-0. PMID:29166901
86. Fischer A, Kong AM, **Swigris JJ**, Cole AL, Raimundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. *J Rheumatol* 2017 Nov 15. pii: jrheum.170307. doi: 10.3899/jrheum.170307. [Epub ahead of print] PMID: 29142033
87. Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, **Swigris JJ**. Understanding the informational needs of patients with IPF and their caregivers: 'You get diagnosed, and you ask this question right away, what does this mean?' *BMJ Open Qual* 2018 Jan 30;7(1):e000207. doi: 10.1136/bmjopen-2017-000207. eCollection 2018. PMID: 29464212
88. Gopalakrishnan V, Jones AM, Julien-Williams P, Machado T, Danner RL, **Swigris JJ**, Paine R 3rd, Lozier JN, Moss J. Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort. *ERJ Open Res.* 2018 Mar 20;4(1). pii: 00121-2017. doi: 10.1183/23120541.00121-2017. eCollection 2018 Jan. PMID:29577040
89. Suzuki A, Kondoh Y, **Swigris JJ**, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. *Respirology.* 2018 Mar 25. doi: 10.1111/resp.13293. [Epub ahead of print] PMID:29575410
90. Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, **Swigris JJ**. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease. *Respir Med.* 2018 May;138:32-37. PMID:29724390
91. Gopalakrishnan V, Jones AM, Julien-Williams P, Machado T, Danner RL, **Swigris JJ**, Paine R 3rd, Lozier JN, Moss J. Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort. *ERJ Open Res.* 2018 Mar 20;4(1). pii: 00121-2017. doi: 10.1183/23120541.00121-2017. eCollection 2018 Jan. PMID:29577040
92. Zhan X, Koelsch T, Montner SM, Zhu A, Vij R, **Swigris JJ**, Chung JH. Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign". *J Thorac Imaging.* 2018 Jul;33(4):266-270. doi: 10.1097/RTI.0000000000000328. PMID:29683868
93. **Swigris JJ**, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. *BMJ Open Respir Res.* 2018 May 18;5(1):e000278. doi: 10.1136/bmjresp-2018-000278. eCollection 2018. PMID: 29862029
94. Nathan SD, Lancaster LH, Albera C, Glassberg MK, **Swigris JJ**, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. *BMJ Open Respir Res.* 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018. PMID:30116539
95. Maher TM, **Swigris JJ**, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and

- Physician Views. *Respiration*. 2018 Aug 16:1-11. doi: 10.1159/000490667. [Epub ahead of print] PMID:30114692
96. Hur SA, Guler SA, Khalil N, Camp PG, Guenette JA, **Swigris JJ**, Ryerson CJ. Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in ILD. *Ann Am Thorac Soc* 2018 Sep 13. doi: 10.1513/AnnalsATS.201804-265OC. [Epub ahead of print] PMID:30211616
 97. Humphries SM, **Swigris JJ**, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA. Quantitative HRCT fibrosis score: Performance characteristics in idiopathic pulmonary fibrosis. *Eur Respir J* 2018 Aug 23. pii: 1801384. doi: 10.1183/13993003.01384-2018. [Epub ahead of print] PMID:30139770
 98. Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, **Swigris JJ**. Rheumatoid Arthritis–Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. *J Rheum*. November 2018, jrheum.171315; DOI: <https://doi.org/10.3899/jrheum.171315>
 99. Suzuki A.; Kondoh Y.; **Swigris J.J.**; Matsuda T.; Kimura T.; Kataoka K.; Ando M.; Hashimoto N.; Sakamoto K.; Hasegawa Y. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. *Respir Med* 2019;150:15-20
 100. Fernández Pérez ER, Sprunger D, Ratanawatkul P, Maier LA, Huie TJ, **Swigris JJ**, Solomon JJ, Mohning M, Keith RC, Brown KK. Increasing Hypersensitivity Pneumonitis-Related Mortality in the United States from 1988 to 2016. *Am J Respir Crit Care Med* 2019 Feb 15. doi: 10.1164/rccm.201807-1258LE. [Epub ahead of print] No abstract available. PMID: 30768910
 101. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, **Swigris JJ**, Bair C, Soon Kim D, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Streck ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Montes Worboys A, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstrong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2019 Apr 29. doi: 10.1164/rccm.201810-1891OC. [Epub ahead of print] PMID:31034279
 102. Kreuter M, **Swigris J**, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagemeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J. The clinical course of idiopathic pulmonary fibrosis and its association to quality

- of life over time: longitudinal data from the INSIGHTS-IPF registry. *Respir Res* 2019 Mar 15;20(1):59. doi: 10.1186/s12931-019-1020-3. PMID:30876420
103. Chartrand S, Lee JS, **Swigris JJ**, Stanchev L, Fischer A. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. *Lung* 2019 Dec;197(6):709-713. doi: 10.1007/s00408-019-00276-7. Epub 2019 Oct 3. PMID:31583453
 104. Pan RL, **Swigris JJ**, Zhao YW, Guo AM, Wu Q, Li SJ. Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease. *Int J Nurs Sci* 2018 Nov 21;6(1):38-42. doi:10.1016/j.ijnss.2018.11.005. eCollection 2019 Jan 10. PMID:31406867
 105. Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, **Swigris JJ**. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. *Chron Respir Dis* 2019 Jan-Dec;16:1479973119858961. doi: 10.1177/1479973119858961. PMID:31288534
 106. Sompornrattanaphan M, Thongngarm T, Ratanawatkul P, Wongsang C, **Swigris JJ**. The contribution of particulate matter to respiratory allergy. *Asian Pac J Allergy Immunol* 2020 Mar;38(1):19-28. doi: 10.12932/AP-100619-0579. PMID: 32105091
 107. Nathan SD, Flaherty KR, Glassberg MK, Raghu G, **Swigris J**, Alvarez R, Ettinger N, Loyd J, Fernandes P, Gillies H, Kim B, Shah P, Lancaster L. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide at a Dose of 30 µg/kg Ideal Body Weight/hr in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis Receiving Oxygen Therapy *Chest* 2020 Feb 21:S0012-3692(20)30327-5. doi: 10.1016/j.chest.2020.02.016. Online ahead of print. PMID: 32092321
 108. Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, **Swigris J**. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. *Respir Res* 2020 Jan 30;21(1):36. doi: 10.1186/s12931-020-1298-1. PMID: 32000772
 109. Solomon JJ, Matson S, Kelmenson LB, Chung JH, Hobbs SB, Rosas IO, Dellaripa PF, Doyle TJ, Poli S, Esposito AJ, Visser A, Marin AI, Amigues I, Fernández Pérez ER, Brown KK, Mahler M, Heinz D, Cool C, Deane KD, **Swigris JJ**, Demoruelle MK. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis. *Chest* 2019 Dec 23:S0012-3692(19)34454-X. doi: 10.1016/j.chest.2019.12.005. Online ahead of print. PMID: 31877269
 110. Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, Carlin B, Drummond MB, Ekström M, Garvey C, Graney BA, Jackson B, Kallstrom T, Knight SL, Lindell K, Prieto-Centurion V, Renzoni EA, Ryerson CJ, Schneidman A, **Swigris J**, Upson D, Holland AE. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2020 Nov 15;202(10):e121-e141. doi: 10.1164/rccm.202009-3608ST. PMID: 33185464
 111. Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, **Swigris JJ**. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. *Eur Respir J* 2020 Oct 2:1902442. doi: 10.1183/13993003.02442-2019. Online ahead of print. PMID: 33008934

112. **Swigris JJ**, Andrae DA, Churney T, Johnson N, Scholand MB, White ES, Matsui A, Raimundo K, Evans CJ. Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *Am J Respir Crit Care Med* 2020 Dec 15;202(12):1689-1697. doi: 10.1164/rccm.202002-0415OC. PMID: 32634038
113. Ratanawatkul P, Oh A, Richards JC, **Swigris JJ**. Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension. *ERJ Open Res* 2020 Feb 10;6(1):00232-2019. doi: 10.1183/23120541.00232-2019. eCollection 2020 Jan. PMID: 32055634
114. Mohning MP, Amigues I, Demoruelle MK, Fernández Pérez ER, Huie TJ, Keith RK, Olson AL, Yunt ZX, Chung JH, Hobbs S, **Swigris JJ**, Solomon JJ. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease. *ERJ Open Res* 2021 Feb 22;7(1):00633-2020. doi: 10.1183/23120541.00633-2020. eCollection 2021 Jan. PMID: 33644223
115. Solomon JJ, **Swigris JJ**, Kreuter M, Polke M, Aronson K, Hoffmann-Vold AM, Dellaripa PF. The Attitudes and Practices of Physicians Caring for Patients with Rheumatoid Arthritis-Interstitial Lung Disease: An International Survey. *Rheumatology (Oxford)*. 2021 Jul 14:keab552. doi: 10.1093/rheumatology/keab552. Online ahead of print. PMID: 34260687
116. Fernández Pérez ER, Crooks JL, **Swigris JJ**, Solomon JJ, Mohning MP, Huie TJ, Koslow M, Lynch DA, Groshong SD, Fier K. Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis. *ERJ Open Res* 2021 Jun 7;7(2):00054-2021. doi: 10.1183/23120541.00054-2021. eCollection 2021 Apr. PMID: 34109243
117. **Swigris J**, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease. *ERJ Open Res* 2021 May 24;7(2):00145-2020. doi: 10.1183/23120541.00145-2020. eCollection 2021 Apr. PMID: 34046493
118. Rahaghi F, Belperio JA, Fitzgerald J, Gulati M, Hallowell R, Highland KB, Huie TJ, Kim HJ, Kolb M, Lasky JA, Southern BD, **Swigris JJ**, de Andrade JA. Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. *Clin Med Insights Circ Respir Pulm Med* 2021 Mar 30;15:11795484211006050. doi: 10.1177/11795484211006050. eCollection 2021. PMID: 33854398
119. King CS, Flaherty KR, Glassberg MK, Lancaster L, Raghu G, **Swigris JJ**, Argula RG, Dudenhofer RA, Ettinger NA, Feldman J, Johri S, Fernandes P, Parsley E, Shah P, Nathan SD. A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. *Ann Am Thorac Soc* 2021 Oct 22. doi: 10.1513/AnnalsATS.202107-864OC. Online ahead of print. PMID: 34678128
120. de Boer E, Petrache I, Goldstein NM, Olin JT, Keith RC, Modena B, Mohning MP, Yunt ZX, San-Millán I, **Swigris JJ**. Decreased Fatty Oxidation and Altered Lactate Production During Exercise in Post-Acute COVID-19 Patients. *Am J Respir Crit Care Med* 2021 Oct 19. doi: 10.1164/rccm.202108-1903LE. Online ahead of print. PMID: 34665688 No abstract available.
121. **Swigris JJ**, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.

- BMJ Open Respir Res* 2022 Mar;9(1):e001167. doi: 10.1136/bmjresp-2021-001167. PMID: 35241434
122. Ha DM, Deng LR, Lange AV, **Swigris JJ**, Bekelman DB. Reliability, Validity, and Responsiveness of the DEG, a Three-Item Dyspnea Measure. *J Gen Intern Med* 2022 Jan 3. doi: 10.1007/s11606-021-07307-1. Online ahead of print. PMID: 34981344
 123. Corte TJ, Lancaster L, **Swigris JJ**, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). *BMJ Open Respir Res* 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026. PMID: 34969771
 124. Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O'Brien EC, Slagle AF, Krasnow A, Reaney M, Baldwin M, Male N, Rohr KB, **Swigris J**, Antoniou K. Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures. *ERJ Open Res* 2022 May 3;8(2):00681-2021. doi: 10.1183/23120541.00681-2021. eCollection 2022 Apr. PMID: 35509443

Books, Reviews, Letters, Editorials

A. Books and Book Chapters

1. **Jeffrey J. Swigris**, Kevin K. Brown. Idiopathic Pulmonary Fibrosis. Elsevier. St. Louis. 2019.
2. Anne E. Holland and **Jeffrey J. Swigris**. The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in the Treatment of Patients with Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide; First Edition. 2013 Editors: Keith C. Meyer and Steven D. Nathan. Springer-Verlag New York, LLC
3. Olga Tourin, **Jeffrey J. Swigris**, Amy L. Olson. Idiopathic Pulmonary Fibrosis: The Natural History and Epidemiology of Disease in the Treatment of Patients with Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide; First Edition. 2013 Editors: Keith C. Meyer and Steven D. Nathan. Springer-Verlag New York, LLC
4. David Sprunger, Zulma Yunt, Amy Olson, **Jeffrey J. Swigris**. Idiopathic Pulmonary Fibrosis: The Natural History and Epidemiology of Disease in the Treatment of Patients with Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide; First Edition. 2018 Editors: Keith C. Meyer and Steven D. Nathan. Springer-Verlag New York, LLC
5. Catherine Wittman and **Jeffrey Swigris**. The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in the Treatment of Patients with Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide; Second Edition. 2018 Editors: Keith C. Meyer and Steven D. Nathan. Springer-Verlag New York, LLC
6. Shikha Mittoo and **Jeffrey J. Swigris**. Pulmonary manifestations of Systemic Lupus Erythematosus (SLE) in Pulmonary Manifestations of Rheumatic Disease: A Comprehensive Guide. 2014 Editors: Paul F. Dellaripa, Aryeh Fischer, Kevin R. Flaherty. Springer, New York, NY
7. Deepa Ramadurai, Yosafe Wakwaya, Bridget Graney, Marjorie Patricia George, Amy L. Olson and Jeffrey J. Swigris in Therapeutic Options for Patient with Idiopathic Pulmonary Fibrosis.

2019. Editors: **Jeffrey J. Swigris** and Kevin K. Brown. Idiopathic Pulmonary Fibrosis. Elsevier. St. Louis, MO.

B. Reviews, Letters, Editorials

1. **Swigris JJ**, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). *J Vasc Surg* 1999;29:928-935
2. **Swigris JJ**, Coulter T, Mehta AC. Endobronchial lipoma. *J Bronchology* 1999;6:277-279
3. **Swigris JJ**, Stoller JK. A review of bronchiectasis. *Clin Pulm Med* 2000;7:223-230
4. **Swigris JJ**, Henig NR. Approach to the patient with Hemoptysis. In Best Practice of Medicine [http://praxis.md]. New York: Praxis Press. 2002 January
5. **Swigris JJ**, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. *Chest* 2002; 122:2150-2164
6. **Swigris JJ**, Kuschner WG, Kelsey JL, Gould MK. Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator. *Chest* 2005;127:275-283
7. **Swigris JJ**, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. *Chest* 2005;127:284-294
8. **Swigris JJ**, Ghamande S, Rice TW, Farver C. Diffuse idiopathic pulmonary neuroendocrine hyperplasia: an interstitial lung disease with airway obstruction. *J Bronchology* 2005;12:62-65
9. **Swigris JJ**, Brown KK. Idiopathic pulmonary fibrosis: a decade of progress. *J Bras Pneumol* 2006;32:249-260
10. **Swigris JJ**, Brown KK. Acute interstitial pneumonia and acute exacerbations of idiopathic pulmonary fibrosis. *Semin Respir Crit Care Med* 2006;27:659-667
11. Sung A, **Swigris JJ**, Sakh A, Raoof, S. High resolution chest tomography in idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: utility and challenges. *Curr Opinion Pulm Med* 2007;13:451-457.
12. **Swigris JJ**, Brown KK. Idiopathic Pulmonary Fibrosis: Recent Advances. *US Respiratory Disease* 2007;56-59.
13. **Swigris JJ**, Fischer A, Gillis JZ, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. *Chest* 2008;133:271-280.
14. **Swigris JJ**, Brown KK. Evaluation of bosentan for idiopathic pulmonary fibrosis. *Exp Rev Respir Med* 2008;2:315-321
15. Dalal S, Fischer A, **Swigris JJ**. Systemic sclerosis-related interstitial lung disease. *Current Respiratory Medicine Reviews* 2008;4:226-232.
16. **Swigris JJ**, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation for idiopathic pulmonary fibrosis: a call for systematic investigation. *Respir Med* 2008;102:1675-1680.
17. de Jesus Perez VA, **Swigris JJ**, Ruoss SJ. Coexistence of primary adenocarcinoma of the lung and Tsukamurella infection: a case report and review of the literature. *Journal of Medical Case Reports* 2008;2:207 (14 Jun 2008)
18. Li HY, Cosgrove GP, **Swigris JJ**. Dyspnea in a 43-year old woman with polycystic kidney disease. *Chest* 2009;135:238-243
19. Li HY, Cosgrove GP, **Swigris JJ**. Response to Dr. Kiitisupamongkol. *Chest* 2009;135:1698
20. **Swigris JJ**, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. *BioDrugs* 2010;24:49-54 PMID: 20055532

21. Mittoo S, Fischer A, Strand V, Meehan R, **Swigris JJ**. Systemic lupus erythematosus-related interstitial lung disease. *Current Rheumatology Reviews* 2010;6:99-107
22. Fischer A, West SG, **Swigris JJ**, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. *Chest* 2010;138:251-256 PMID: 20682528
23. **Swigris JJ**, Brown KK, Flaherty KR. The idiopathic interstitial pneumonias and connective tissue disease-associated interstitial lung disease. *Current Rheumatology Reviews* 2010;6:91-98
24. **Swigris JJ** and Fairclough D. Pirfenidone in IPF. *Eur Respir J* 2010;36:695-696 doi:10.1183/09031936.00071710
25. Solomon J, **Swigris JJ**, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. *J Bras Pneumol* 2011;37:100-109 PMID:21390438
26. Fischer A, West SG, **Swigris JJ**, Brown KK, du Bois RM. Response to Teramoto and colleagues. *Chest* 2011;139:723
27. Solomon J, **Swigris JJ**. Pulmonary hypertension in idiopathic pulmonary fibrosis. *Ann Respir Med* 2012;2(II)
28. **Swigris JJ** and Fairclough D. Patient-reported Outcomes in Idiopathic Pulmonary Fibrosis Research. *Chest* 2012;142(2):291-297 PMID: 22871754
29. Olson AL, **Swigris JJ**. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. *Clin Chest Med* 2012;33:41-50 PMID: 22365244
30. **Swigris JJ**, Olson AL. Response to Vorselaars et al. *Chest* 2012;141:827
31. Olson AL, **Swigris JJ**, Brown KK. Clinical trials and tribulations—lessons from pulmonary fibrosis. *QJM* 2012;105:1043-7 PMID: 22647760
32. Gutsche M, Rosen GD, **Swigris JJ**. Connective tissue disease-associated interstitial lung disease: a review. *Curr Respir Care Rep* 2012;1:224-232 PMID: 23125954
33. Brown KK, Fischer A, **Swigris JJ**. Preface. *Immunol Allergy Clin N Amer* 2012; 32:xi-xii. DOI:10.1016/j.iac.2012.09.001
34. Neto MLR, **Swigris JJ**, and Culver DA. Idiopathic pulmonary fibrosis or not: antibiotic prophylaxis for all patients on immunosuppressants. *Thorax*. published 5 April 2013, 10.1136/thoraxjnl-2013-203395 PMID:23564341
35. **Swigris JJ**, Brown KK, Belkin A. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. *Ann Intern Med* 2013;158:498.PMID:23552975
36. Belkin A, **Swigris JJ**. Health-related Quality of Life in Idiopathic Pulmonary Fibrosis: Where are we now? *Curr Opin Pulm Med*. 2013 Sep;19(5):474-9. Doi: 10.1097/MCP.0b013e328363f479. PMID: 23851327
37. Antin-Ozerkis D, **Swigris JJ**. Preface: Pulmonary Complications of Connective Tissue Disease. *Semin Respir Crit Car Med* 2014;35:157-158
38. Belkin A, **Swigris JJ**. Patient expectations and experiences in idiopathic pulmonary fibrosis: implications of patient surveys for improved care. *Expert Rev Respir Med* 2014;8:173-8. doi: 10.1586/17476348.2014.880056. PMID: 24450476
39. **Swigris JJ**, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. *Health Qual Life Outcomes* 2014 Aug 20;12(1):124. doi: 10.1186/s12955-014-0124-1. PMID:25138056

40. Russell AM, Sprangers MA, Wibberley S, Snell N, Rose DM, **Swigris JJ**. The need for patient-centred clinical research in idiopathic pulmonary fibrosis. *BMC Med* 2015 Sep 24;13:240. doi: 10.1186/s12916-015-0475-4. PMID:26399318
41. Russell AM, **Swigris JJ**. What's it like to live with idiopathic pulmonary fibrosis? Ask the experts. *Eur Respir J* 2016;47:1324-1326
42. Olson AL, Brown KK, **Swigris JJ**. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. *Patient Related Outcomes Measures* 2016;7:29-35
43. Lederer DJ, **Swigris JJ**. Idiopathic Pulmonary Fibrosis on the Internet. Let's Calm the Sea of (Mis)information. *Am J Respir Crit Care Med* 2016 Jul 15;194(2):134-6. doi: 10.1164/rccm.201601-0190ED.
44. Maier LA, Liu H, Patel D, Welch A, Wilson C, Mroz M, Li L, Rose C, VanDyke M, **Swigris J**, Hamzeh N. Response. *Chest* 2016 Dec;150(6):1423-1424. doi: 10.1016/j.chest.2016.10.004. PMID:27938764
45. **Swigris JJ**. Caution against Extrapolating Results from the Trial of Long-Term Oxygen for Chronic Obstructive Pulmonary Disease. *Ann Am Thor Soc* 2017;14:296
46. **Swigris JJ**. Supplemental Oxygen for Patients with Interstitial Lung Disease: Managing Expectations. *Ann Am Thor Soc* 2017;14:831-832. jdoi.org/10.1513/AnnalsATS.201703-236ED
47. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, **Swigris JJ**, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers* 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review. PMID:29052582
48. Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, **Swigris J**, Udwardia Z, Wells A, Wijsenbeek M. Palliative care in interstitial lung disease: living well. *Lancet Respir Med* 2017 Dec;5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. Epub 2017 Oct 13. Review. PMID:29033267
49. **Swigris J**. DELPHIning Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. *Am J Respir Crit Care Med* 2017 Dec 20. doi: 10.1164/rccm.201712-2403ED. [Epub ahead of print] No abstract available. PMID:29262259
50. **Swigris JJ**. Transitions and touchpoints in idiopathic pulmonary fibrosis. *BMJ Open Resp Res* 2018;5:e000317. doi: 10.1136/bmjresp-2018-000317
51. **Jeffrey J. Swigris**. A patient-centered approach to care in chronic disease. *Am J Med Sci Am J Med Sci*. 2019 Feb;357(2):85-86. doi: 10.1016/j.amjms.2018.08.008. Epub 2018 Aug 21. No abstract available. PMID: 30278878
52. **Jeffrey J Swigris**. A New Tool to Capture Patients' Perceptions of the Effects of Lung Transplantation. *Am J Respir Crit Care Med* 2019 Apr 15;199(8):941-943. PubMed: 30457877.
53. **Swigris JJ**, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. *Eur Respir Rev* 2018 Dec 21;27(150). pii: 180075. doi: 10.1183/16000617.0075-2018. Print 2018 Dec 31. Review. PMID:30578334
54. Jacobs SS, Lederer DJ, Garvey CM, Hernandez C, Lindell KO, McLaughlin S, Schneidman AM, Casaburi R, Chang V, Cosgrove GP, Devitt L, Erickson KL, Ewart GW, Giordano SP, Harbaugh M, Kallstrom TJ, Kroner K, Krishnan JA, Lamberti JP, Porte P, Prieto-Centurion V, Sherman

- SE, Sullivan JL, Sward E, **Swigris JJ**, Upson DJ. Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc* 2018 Dec;15(12):1369-1381. doi: 10.1513/AnnalsATS.201809-627WS. PMID:30499721
55. **Swigris JJ**. Towards a refined definition of combined pulmonary fibrosis and emphysema. *Respirology* 2019 Jan;24(1):9-10. doi: 10.1111/resp.13426. Epub 2018 Oct 15. No abstract available. PMID:3032471
56. Wijsenbeek MS, Holland AE, **Swigris JJ**, Renzoni EA. Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease. *Am J Respir Crit Care Med* 2019 May 3. doi: 10.1164/rccm.201903-0614PP. [Epub ahead of print] PMID:31051080
57. Chernau AK, Leone PM, **Swigris JJ**. Interstitial Pneumonia with Autoimmune Features and Undifferentiated Connective Tissue Disease. *Semin Respir Crit Care Med* 2019 Apr;40(2):271-277. doi: 10.1055/s-0039-1684007. Epub 2019 May 28. PMID:31137065
58. Amigues I, Ramadurai D, **Swigris JJ**. Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease. *Open Access Rheumatol* 2019 Oct 15;11:229-235. doi: 10.2147/OARRR.S166070. eCollection 2019. PMID:31686925
59. **Swigris JJ**. The 4-min mile and supplemental oxygen in IPF. *Respirology* 2020 Nov;25(11):1114-1115. doi: 10.1111/resp.13890. Epub 2020 Jun 22. PMID: 32573005
60. Aronson KI, **Swigris JJ**. How Do We Define a Meaningful Change in Quality of Life for Patients with Sarcoidosis? *Ann Am Thorac Soc* 2021 Mar;18(3):417-418. doi: 10.1513/AnnalsATS.202010-1241ED. PMID: 33646080
61. Guler SA, Lindell KO, **Swigris J**, Ryerson CJ. Nondrug Treatments for Idiopathic Pulmonary Fibrosis: IPF Part 3. *Am J Respir Crit Care Med* 2021 Feb 1;203(3):P7-P8. doi: 10.1164/rccm.2033P7. PMID: 33522880
62. Guler SA, Lindell KO, **Swigris J**, Ryerson CJ. What Is Idiopathic Pulmonary Fibrosis? IPF Part 1. *Am J Respir Crit Care Med* 2021 Jan 15;203(2):P5-P6. doi: 10.1164/rccm.2032P5. PMID: 33448890
63. Solomon JJ, **Swigris JJ**, Demoruelle MK. Response. *Chest* 2020 Oct;158(4):1778-1779. doi: 10.1016/j.chest.2020.07.048. PMID: 33036088
64. Antoniou K, Kamekis A, Symvoulakis EK, Kokosi M, **Swigris JJ**. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. *Curr Opin Pulm Med* 2020 Sep;26(5):457-463. doi: 10.1097/MCP.0000000000000703. PMID: 32701673
65. Wakwaya Y, Ramdurai D, **Swigris JJ**. How we do it: Managing cough in idiopathic pulmonary fibrosis. *Chest* 2021 Jun 22:S0012-3692(21)01159-4. doi: 10.1016/j.chest.2021.05.071. Online ahead of print. PMID: 34171385
66. Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, Lindell KO, Maher TM, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, **Swigris JJ**. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. *Am J Respir Crit Care Med* 2021 Jul 15;204(2):e3-e23. doi: 10.1164/rccm.202105-1193ST. PMID: 34283696

Abstracts (selected)

Swigris JJ, Gould MK, Wilson SR. Provisional domains for an idiopathic pulmonary fibrosis (IPF) specific health-related quality of life (HRQL) instrument: the IPF self-administered questionnaire (IPF-SAQ). *Chest* 2004;126:771S-772S

Sankaranarayanan V, **Swigris JJ**, Cobb K, Theodore J, Henig NR. Marginal donor lungs do not affect overall survival in lung transplantation. *Am J Respir Crit Care Med* 2004;169:A270

Swigris JJ, Kushner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF): a systematic review (SR). *Proc Am Thor Soc* 2005;2,A386

Swigris JJ, Kushner WG, Jacobs SS, Wilson SR, Gould MK. Correlations between health-related quality of life (HRQL) and disease severity measures in patients with idiopathic pulmonary fibrosis (IPF): data from a systematic review (SR). *Proc Am Thor Soc* 2005;2,A386

Baughman RP, Rosen G, Horton MR, **Swigris JJ**, Jacobs SS, Krishna G, Polito AJ, Danoff SK, Lower EE. Thalidomide for idiopathic pulmonary fibrosis: an open-label trial. *Proc Am Thor Soc* 2005;2,A124

Swigris JJ, Olson AL, Fischer A, Frankel S, Cosgrove G, Meehan RT, Brown KK. Mycophenolate mofetil for the treatment of connective tissue disease (CTD)-related interstitial lung disease (ILD). *Proc Am Thor Soc* 2006;3:A723

Swigris JJ, Behr J, Brown KK, duBois R, King, Jr TE, Raghu G. Longitudinal trends in dyspnea in patients with idiopathic pulmonary fibrosis (IPF): The BUILD 1 study. *Chest* 2006;130:282Sa

Olson AL, **Swigris JJ**, Lezotte D, Norris J, Wilson C, Brown KK. Mortality Rates from Pulmonary Fibrosis (PF) Steadily Increased Over the Period from 1992 to 2003. *Am J Resp Crit Care Med* 2007;175:A142.

Olson AL, **Swigris JJ**, Lezotte D, Norris J, Wilson C, Brown KK. The underlying cause-of-death in decedents with pulmonary fibrosis, 1992 -2003. *Am J Resp Crit Care Med* 2007;175:A569.

Olson AL, **Swigris JJ**, Lezotte D, Norris J, Wilson C, Brown KK. Mortality rates predicted to increase in decedents with pulmonary fibrosis. *Am J Resp Crit Care Med* 2007;175:A143.

Fischer A, Groshong SD, Cool C, Curran-Everett D, **Swigris JJ**, Frankel SK, Cosgrove GP, Meehan RT, Brown KK. Histopathologic patterns and survival in systemic sclerosis(SSc)-interstitial lung disease (ILD) compared with idiopathic interstitial pneumonia (IIP). *Am J Respir Crit Care Med* 2007;175:A366.

Fischer A, **Swigris JJ**, Meehan RT, Groshong SD, Cool C, Cosgrove GP, Frankel SK, Brown KK. Labial salivary gland biopsy (LBx) may identify seronegative sjogren's syndrome (SS) in patients with idiopathic interstitial lung disease (iILD). *Am J Respir Crit Care Med* 2007;175:A297.

Gillis J, **Swigris JJ**. Systemic Lupus Erythematosus (SLE)-Associated Chronic Lung Disease (CTD). *Am J Respir Crit Care Med* 2008;177:A884

Olson AL, **Swigris JJ**, Raghu G, Brown KK. Seasonal Variation: Mortality from Pulmonary Fibrosis Is Greatest in the Winter. *Am J Resp Crit Care Med* 2008;177:A249.

Sprunger D, Talbert J, Brown KK, **Swigris JJ**. Cognitive function is impaired in patients with idiopathic pulmonary fibrosis. *Am J Resp Crit Care Med* 2009;179:A4059

Fischer A, **Swigris JJ**, Frankel SK, Cosgrove GP, Gillis JZ, Brown KK. A Nucleolar-Pattern ANA in Patients with Idiopathic Interstitial Pneumonia Suggests Underlying Connective Tissue Disease. *Am J Resp Crit Care Med* 2009;179:A4492

Fischer A, **Swigris JJ**, Cosgrove GP, Gillis JZ, Frankel SK, Brown KK. PL-7 and PL-12 Auto-Antibodies in Patients Presenting with Interstitial Lung Disease (ILD). *Am J Resp Crit Care Med* 2009;179:A3946

Swigris JJ, Zhou X, Keith R, Fischer A, Cosgrove GP, Frankel SK, Brown KK. Exercise SpO2 Predicts Mortality in Systemic Sclerosis. *Am J Resp Crit Care Med* 2009;179:A4498

Swigris JJ, Swick J, Wamboldt FS, Kervitsky D, Brown KK. Heart Rate Recovery (HRR) after 6MWT Predicts Survival in Patients with IPF. *Am J Resp Crit Care Med* 2009;179:A1122

Swigris JJ, Wamboldt FS, Behr J, du Bois R, King, Jr TE, Raghu G, Brown KK. 6MWT in IPF: longitudinal changes and MID. *Am J Resp Crit Care Med* 2009;179:A1123

Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart Rate Recovery after 6MWT Predicts Pulmonary Hypertension in Patients with IPF. *Am J Resp Crit Care Med* 2010;181:A1111

Joshua J. Solomon, Allen Stevens, Mary Gill, Evans Fernandez-Perez, Tristan Huie, Amy L. Olson, **Jeffrey J. Swigris**, Kevin K. Brown, Richard Martin, Ronald M. du Bois, and Aryeh Fischer. Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibody Positivity In Patients With Lung Disease, Without Rheumatoid Arthritis (RA) Or Other Connective Tissue Disease (CTD). *Am J Respir Crit Care Med* 2011;183:A2334.

Joshua J. Solomon, Allen Stevens, Mary Gill, **Jeffrey J. Swigris**, Amy L. Olson, Tristan Huie, Evans Fernandez-Perez, Richard Martin, Kevin K. Brown, and Aryeh Fischer. Patterns Of Lung Disease In Patients With Rheumatoid Arthritis (RA) And Different Autoantibody Profiles. *Am J Respir Crit Care Med* 2011; 183:A2348.

Amy L. Olson, David Sprunger, Tristan Huie, Evans Fernandez-Perez, Aryeh Fischer, Joshua J. Solomon, Kevin K. Brown, and **Jeffrey J. Swigris**. The Prevalence Of Venous Thromboembolism (VTE) In Pulmonary Fibrosis (PF). *Am J Respir Crit Care Med* 2011;183:A5305.

Evans R. Fernandez Perez, **Jeffrey J. Swigris**, Aryeh Fischer, Joshua J. Solomon, Amy L. Olson, Kevin K. Brown, Tristan Huie, Stephen K. Frankel, and Richard T. Meehan. FEV1 Trend In Patients With Connective Tissue Disease (CTD) Related Bronchiolitis (CTD-B). *Am J Respir Crit Care Med* 2011; 183:A1304.

Jeffrey J. Swigris, Amy L. Olson, Tristan Huie, Evans Fernandez-Perez, Joshua J. Solomon, David Sprunger, and Kevin K. Brown. Sarcoidosis Mortality In The U.S. From 1988-2007. *Am J Respir Crit Care Med* 2011;183:A5628.

Jeffrey J. Swigris, Amy L. Olson, Evans Fernandez-Perez, Tristan Huie, Joshua J. Solomon, David Sprunger, and Kevin K. Brown. Sarcoidosis Is A Risk Factor For Pulmonary Embolism (PE). *Am J Respir Crit Care Med* 2011;183:A5637.

Joshua J. Solomon, Jay Ryu, Henry Tazelaar, Jeffrey L. Myers, Rubin Tuder, Carlyne Cool, **Jeffrey J. Swigris**, and Kevin K. Brown. Fibrosing Interstitial Pneumonia Predicts Survival In Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). *Am J Respir Crit Care Med* 2011; 183:A3029.

Shikha Mittoo, Lesley Ann Saketkoo, **Jeffery J. Swigris**, Daphne LeSage, Aryeh Fischer and Sid Frankel. Living with Connective Tissue Related Interstitial Lung Disease: Patient Experiences of the Disease Process Over Time. Abstract #24092 American College of Rheumatology Meeting; Chicago, IL; November 2011.

Aryeh Fischer, Mahalakshmi Krishnamoorthy, Amy L. Olson, Joshua J. Solomon, Evans R. Fernandez-Perez, Tristan J. Huie, Stephen K. Frankel, Gregory P. Cosgrove, Richard T. Meehan, Roland M. du Bois, Kevin K. Brown, and **Jeffrey J. Swigris**. Mycophenolate Mofetil (MMF) In Various Interstitial Lung Diseases (ILD). *Am J Respir Crit Care Med* 2012;185:A3638.

Ana Zamora, Amy L. Olson, Kevin K. Brown, Michael Van Dyke, Lisa A. Maier, and **Jeffrey J. Swigris**. Occupational Exposures (OE) And Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2012; 185:A5176.

Maithy Tran, Lesley Ann Saketkoo, Sid Frankel, Aryeh Fischer, **Jeffrey J. Swigris**, Edward Keystone, Theodore K. Marras, Matthew Binnie, Shane Shapera, Jakov Moric, Stephen Juvet, and Shikha Mittoo. Patients' Perspectives Of Living With Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). *Am J Respir Crit Care Med* 2012;185:A6608.

Evans R. Fernandez Perez, **Jeffrey J. Swigris**, Amy L. Olson, Joshua J. Solomon, and Kevin K. Brown. The Effect Of Identifying An Offending Antigen (OA) On Survival In Chronic Hypersensitivity Pneumonitis (cHP). *Am J Respir Crit Care Med* 2012;185:A4688.

Joshua J. Solomon, Gloria M. Russell, Jill B. Ketzer, Amy L. Olson, Evans R. Fernandez-Perez, Tristan J. Huie, **Jeffrey J. Swigris**, Kevin K. Brown and Aryeh Fischer. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Spectrum of a Large Cohort From A Respiratory Referral Center. *ACR* 2012

Shikha Mittoo, Sid Frankel, Daphne LeSage, Flavia V. Castelino, Lisa Christopher-Stine, Sonye Danoff, Aryeh Fischer, Laura K. Hummers, Ami A. Shah, **Jeffery J. Swigris**, Sophia Cenac, Sancia Ferguson, Ignacio Garcia-Valladares, Maithy Tran, Harmanjot K. Grewal and Lesley Ann Saketkoo. Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease. *Arthritis and Rheumatism. Conference:*

Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology HealthProfessionals 2012: S630-S63

Saketkoo LA, Mittoo S, Huscher D, Dellaripa PF, Denton CP, Distler O, Fischer A, Flaherty KR, Frankel S, Khanna D, Kowal-Bielecka O, LeSage D, Merkel P, Oddis CV, Phillips K, Pittrow D, Sarver C, Sandorfi N, Christmann N, **Swigris J**, Wells AU, Antoniou K., Baughman RP, Castellino FV, Christopher-Stine L, Danoff S, Highland KB, Hummers L, Shah A, Kim DS, Lynch D, Miller FW, Proudman S, Richeldi L, Ryu JH, Seibold JR, Strand V, Matteson EL, Brown KK. Provisional Consensus On Domains and Instruments in Connective Tissue Disease Related Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis For Use in Clinical Trials. *American Thoracic Society International Conference*. Philadelphia 2013

S.D. Nathan, MD¹, C. Albera, MD², W.Z. Bradford, MD³, U. Costabel, MD⁴, R.M. Du Bois, MD⁵, E.A. Fagan, M.D.³, I. Glaspole, MD⁶, M.K. Glassberg, MD⁷, T.E. King, MD⁸, L. Lancaster, MD⁹, D.J. Lederer, MD, MS¹⁰, Z. Lin, PhD³, C.A. Pereira, MD¹¹, J.J. Swigris, DO, MS¹², D. Valeyre, MD¹³, P.W. Noble, MD¹⁴ Effect of Continued Treatment with Pirfenidone Following a Clinically Meaningful Decline in Percent Predicted Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF), [Publication Page: A1016]

L. Lancaster, MD¹, C. Albera, MD², W.Z. Bradford, MD³, U. Costabel, MD⁴, R.M. Du Bois, MD⁵, E.A. Fagan, M.D.³, I. Glaspole, MD⁶, M.K. Glassberg, MD⁷, T.E. King, MD⁸, D.J. Lederer, MD, MS⁹, Z. Lin, PhD³, C.A. Pereira, MD¹⁰, J.J. Swigris, DO, MS¹¹, D. Valeyre, MD¹², P.W. Noble, MD¹³ Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Integrated Analysis of Data from 5 Clinical Trials, [Publication Page: A1017]

C. Albera, MD¹, W.Z. Bradford, MD², U. Costabel, MD³, E.A. Fagan, M.D.², I. Glaspole, MD⁴, M.K. Glassberg, MD⁵, E. Gorina, PhD², D. Kardatzke, PhD², T.E. King, MD⁶, L. Lancaster, MD⁷, D.J. Lederer, MD, MS⁸, S.D. Nathan, MD⁹, C. Pereira, MD¹⁰, D. Spirig, PhD¹¹, J.J. Swigris, DO, MS¹², D. Valeyre, MD¹³, P.W. Noble, MD¹⁴ Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease, [Publication Page: A1018]

S. Matson, MD¹, K. Demoruelle, MD¹, J. Ketzer, BA², A.L. Olson, MD², E.R. Fernandez Perez, MD, MS², T. Huie, MD², L. Peykova, BA², G.M. Russell, M.S.³, A. Mannina, M.S.², A. Fischer, MD², K.D. Deane, MD², K.K. Brown, MD², J.J. Swigris, DO, MS², J.J. Solomon, MD² The Predictive Value of CCP Antibodies in Rheumatoid-Arthritis Interstitial Lung Disease, [Publication Number: A1157]

J.J. Solomon, MD¹, K. Demoruelle, MD², A. Mannina, M.S.¹, A.L. Olson, MD¹, A. Fischer, MD¹, E.R. Fernandez Perez, MD, MS¹, T. Huie, MD¹, J. Chung, MD³, K.D. Deane, MD¹, G.M. Russell, M.S.⁴, Y. Tsuchiya, M.D.¹, K.K. Brown, MD¹, J.J. Swigris, DO, MS¹ Predictors of Outcome in Rheumatoid Arthritis- Associated Interstitial Lung Disease, [Publication Number: A1160]

S. Chartrand, MD, FRCPC, J.J. Swigris, DO, MS, L. Peykova, MS, A. Fischer, MD A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease vs. Idiopathic Pulmonary Fibrosis, [Publication Number: A1166]

S. Chartrand, MD, FRCPC, J.J. Swigris, DO, MS, L. Peykova, MS, A. Fischer, MD A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia, [Publication Number: A1167]

S. Chartrand, MD, FRCPC, J.J. Swigris, DO, MS, L. Peykova, MS, A. Fischer, MD Rituximab Treatment for Chronic Connective Tissue Disease-Associated Interstitial Lung Disease, [Publication Number: A1168]

Y. Tsuchiya, M.D.¹, D.A. Lynch, MD¹, S.D. Groshong, MD¹, T.V. Colby, MD², J. Fukuoka, MD³, T. Johkoh, PhD⁴, K.S. Lee, M.D. Ph.D.⁵, H. Taniguchi, M.D.⁶, Y. Kondoh, MD⁶, K. Kataoka, PhD⁶, A. Shiraki, MD, PhD⁷, N. Tanaka, M.D.⁸, K. Ichikado, MD⁹, K. Fujimoto, MD¹⁰, H. Arakawa, medicine¹¹, Y. Waseda, MD, PhD¹², A. Wakabayashi, M.D.¹³, F. Kokubu, MD¹⁴, K.K. Brown, MD¹, A. Fisher, M.D.¹, J.J. Swigris, DO, MS¹, J.J. Solomon, MD¹ Usual Interstitial Pneumonia Preceding Rheumatoid Arthritis: Clinical and Histologic Features, [Publication Number: A1171]

X. Zhan, PhD, MD¹, A.L. Olson, MD², E.R. Fernandez-Perez, MD², T.J. Huie, MD², J.J. Swigris, DO, MS², K.K. Brown, MD², J.J. Solomon, MD² Anti-Cyclic Citrullinated Peptide Antibody Positivity In Non-RA Patients with Lung Disease: Does It Matter?, [Publication Number: A1172]

Z. Yunt, MD, J.J. Solomon, MD, J.J. Swigris, DO, MS, J. Chung, MD Confidence in Usual Interstitial Pneumonia (UIP) Pattern on High Resolution Computed Tomography (HRCT) Predicts Mortality in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), [Publication Number: A6313]

T. Farnsworth, MPH, J.J. Swigris, DO, MS Oxygen Users with Pulmonary Fibrosis (PF) Perceive More Shortness of Breath (SOB) than Non-Oxygen Users with Equivalent Disease Severity, [Publication Number: A1559]

T. Walker, MD, MPH¹, K. Albright, PhD¹, J.J. Swigris, DO, MS² Engaging Interstitial Lung Disease (ILD) Patients in a Web 2.0 Environment, [Publication Number: A2207]

T. Walker, MD, MPH¹, M.I. Schwarz, MD¹, D.A. Schwartz, MD¹, J.J. Swigris, DO, MS² Pilot Study to Assess the Feasibility and Impact of Electronic Messaging in Patients with ILD, [Publication Number: A2208]

K. Raimundo, MS¹, E. Chang, PhD², M. Broder, MD, MSHS², G. Carrigan, PhD, MS¹, J. Zazzali, PHD, MPH¹, J.J. Swigris, DO, MS³ Clinical and Economic Burden of Idiopathic Pulmonary Fibrosis, [Publication Number: A2521]

K. Raimundo, MS¹, E. Chang, PhD², M. Broder, MD, MSHS², G. Carrigan, PhD, MS¹, J. Zazzali, PHD, MPH¹, J.J. Swigris, DO, MS³ Prevalence and Clinical Characteristics of Idiopathic Pulmonary Fibrosis, [Publication Number: A4380]

D. Berry, PhD¹, C. Albera, MD², W.Z. Bradford, MD³, U. Costabel, MD⁴, R. Du Bois, MD⁵, I. Glaspole, MD⁶, M.K. Glassberg Csete, MD⁷, L. Lancaster, MD⁸, D.J. Lederer, MD, MS⁹, Z. Lin, PhD³, S.D. Nathan, MD¹⁰, J.J. Swigris, DO, MS¹¹, D. Valeyre, MD¹², P.W. Noble, MD¹³ Pirfenidone Impact on Mortality in IPF Patients: Bayesian Analysis, [Publication Number: A4417]

E. Root, PhD¹, K. Albright, PhD², F.S. Wamboldt, MD³, J.J. Swigris, DO, MS³ Does Supplemental Oxygen Expand ILD Patients' Worlds? Assessment by Global Positioning System (GPS) and Accelerometry, [Publication Number: A5205]